East-West Summit Highlights, Part 2: a BioCentury podcast

Agio Capital’s Henk Joos, Immune-Onc’s Charlene Liao discuss navigating the ‘biotech winter’

As China’s biopharma companies experience their first “biotech winter,” they should be engaged in active portfolio management, stopping projects that will not meet their investors’ expectations, Agio Capital General Manager Henk Joos said on BioCentury This Week. On a special East-West Summit edition of the podcast, Joos and Immune-Onc Therapeutics Inc. founder and CEO Charlene Liao discussed pipeline prioritization and other company survival tactics during today’s difficult financing environment.

On Tuesday, Liao’s company, which is based in the San Francisco Bay Area, won the BayHelix Award for R&D Achievement of the Year.